Preview Mode Links will not work in preview mode


Sep 10, 2020

Convalescent plasma has been a hot button news story over the past few weeks since the FDA approved its use in COVID patients. In this episode, hematologist Tom DeLoughery (@Bloodman) breaks down what it is, what it purportedly does, the evidence (or lack thereof) supporting its use, at what point in disease it might work, and potential dangers of indiscriminate use. 

This episode is brought to you by Mar-Med, makers of the industry leading and #1 selling Tourni-Cot digital tourniquet. What you may not know is that Mar-Med also  makes a newly reengineered balloon extractor for nasal foreign bodies, a one size fits all Uni-Cot digital tourniquet, and the Derma-Stent drain that greatly simplifies loop abscess procedures. I’ve used Mar-Med’s products hundreds of times and can attest to their efficacy and simplicity of use. You can check out all of their products and get free samples of whatever you’d like to try at Who doesn’t love free samples, especially when it’s awesome stuff? 

We Discuss

  • What is convalescent plasma (CP)? [04:06];
  • How plasmapheresis can collect large volumes of donor plasma [4:53];
  • If donating plasma (and losing antibodies) can make one more susceptible to infection [5:32];
  • The potential folly of using CP in only the sickest patients and why it might be better used at the beginning of illness [06:25];
  • How much immunity a single unit of plasma might provide [10:51];
  • Adverse consequences of plasma use [12:00];
  • Does CP actually work? [14:16];
  • Would Tom want CP if he got COVID? [21:35];
  • What we’ve learned from the massive effort to accelerate CP collection [23:02];
  • And More.


For Show Notes, previous episodes, or to sign up for our newsletter:

If you like what you hear on Stimulus and use Apple/iTunes as your podcatcher, please consider leaving a review of the show. I read all the reviews and, more importantly, so do potential guests. Thanks in advance!

Interested in sponsoring this podcast? Connect with us here

Follow Rob: